Immune privilege of corneal allografts

Ocular Immunology and Inflammation

Volumn 18, Issue 3, 2010, Pages 162-171

  Niederkorn, Jerry Y ^a   Larkin, D Frank P ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Corneal allografts; Immune privilege; Keratoplasty; Transplantation

Indexed keywords

COMPLEMENT; FAS LIGAND; HLA ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MEMBRANE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; REGULATOR PROTEIN; VASCULOTROPIN RECEPTOR 2;

ALLOTRANSPLANTATION; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ATOPY; BLOCKING FACTOR; CLINICAL TRIAL; CORNEA TRANSPLANTATION; CORNEA VASCULARIZATION; EFFECTOR CELL; GENE TRANSFER; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KERATITIS; KERATOCONUS; LYMPHADENECTOMY; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; SENSORY NERVE CONDUCTION;

CORNEA; CORNEAL DISEASES; CORNEAL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, CELLULAR; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952862051     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.486100     Document Type: Review

References (80)

1. America EBA. Statistical Report on Eye Banking Activity for 2008. www.restoresightorg/donation/statisticshtm 2008.
2. Zirm E. Eine erfolgreiche totale Keratoplastik. Albrecht von Graefes Arch Ophthalmol. 1906;64:580-593.
3. Billingham RE, Boswell T. Studies on the problem of corneal homografts. Proc R Soc Lond B Biol Sci. 1953;141(904): 392-406.
4. Medawar PB. Immunity to homologous grafted skin, III: the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58-69.
5. Niederkorn JY. Immunoregulation of intraocular tumours. Eye. 1997;11(Pt 2):249-254.
6. Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res. 2009;28(5):329-347.
7. Niederkorn JY, Meunier PC. Spontaneous immune rejection of intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1985;26(6):877-884.
8. Niederkorn JY, Wang S. Immunology of intraocular tumors. Ocul Immunol Inflamm. 2005;13(1):105-110.
9. Dace DS, Chen PW, Alizadeh H, et al. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner. J Leukoc Biol. 2007;81(2):421-429.
10. Knisely TL, Luckenbach MW, Fischer BJ, et al. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol. 1987;138(12):4515-4523.
11. Knisely TL, Niederkorn JY. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. Cancer Immunol Immunother. 1990;30(6):323-330.
12. George AJ, Larkin DF. Corneal transplantation: the forgotten graft. Am J Transplant. 2004;4(5):678-685.
13. Hori J, Joyce NC, Streilein JW. Immune privilege and immunogenicity reside among different layers of the mouse cornea. Invest Ophthalmol Vis Sci. 2000;41(10): 3032-3042.
14. Niederkorn JY. The immune privilege of corneal allografts. Transplantation. 1999;67(12):1503-1508.
15. Niederkorn JY. The immunology of corneal transplantation. Dev Ophthalmol. 1999;30:129-140
16. Niederkorn JY. Immunology and immunomodulation of corneal transplantation. Intern Rev Immunol. 2002;21(173- 196):173-196.
17. Niederkorn JY. The immune privilege of corneal grafts. J Leukoc Biol. 2003;74(2):167-171.
18. Williams KA, Coster DJ. Rethinking immunological privilege: implications for corneal and limbal stem cell transplantation. Mol Med Today. 1997;3(11):495-501.
19. Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation. 2007;84(7):806-813.
20. Group CCTSR. The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110(10):1392-1403.
21. Streilein JW. New thoughts on the immunology of corneal transplantation. Eye. 2003;17(8):943-948.
22. She SC, Steahly LP, Moticka EJ. A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse. Ophthalmic Surg. 1990;21(11):781-785.
23. Williams KA, Coster DJ. Penetrating corneal transplantation in the inbred rat: a new model. Invest Ophthalmol Vis Sci 1985;26(1):23-30.
24. He YG, Niederkorn JY. Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea. 1996;15(1):82-89.
25. Yamada J, Yoshida M, Taylor AW, et al. Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in "high risk" eyes. J Immunol. 1999;162(9):5247-5255.
26. Williams KA, Muehlberg SM, Lewis RF, et al. Long-term outcome in corneal allotransplantation. The Australian Corneal Graft Registry. Transplant Proc. 1997;29(1-2):983.
27. Waldock A, Cook SD. Corneal transplantation: how successful are we? Br J Ophthalmol. 2000;84(8):813-815.
28. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2009;184(2): 535-539.
29. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113(7):1040-1050.
30. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2(8): 573-583.
31. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103(30):11405-11410.
32. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med. 2009;15(9):1023-1030.
33. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7(4):354-359.
34. Niederkorn JY. Anterior chamber-associated immune deviation and its impact on corneal allograft survival. Curr Opin Organ Transplant. 2006;11:360-365.
35. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879-889.
36. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol. 2007;92:71-85.
37. Sonoda Y, Ksander B, Streilein JW. Evidence that active suppression contributes to the success of H-2-incompatible orthotopic corneal allografts in mice. Transplant Proc. 1993;25(1 Pt 2):1374-1376.
38. Sonoda Y, Streilein JW. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol. 1993;150(5):1727-1734.
39. Skelsey ME, Mellon J, Niederkorn JY. Gamma delta T cells are needed for ocular immune privilege and corneal graft survival. J Immunol. 2001;166(7):4327-4333.
40. Sonoda KH, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1dreactive NKT cells. J Immunol. 2002;168(4):2028-2034.
41. Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci. 1996;37(13):2700-2707. (Pubitemid 27026555)
42. She SC, Moticka EJ. Ability of intracamerally inoculated B- and T-cell enriched allogeneic lymphocytes to enhance corneal allograft survival. Int Ophthalmol. 1993;17(1):1-7.
43. She SC, Steahly LP, Moticka EJ. Intracameral injection of allogeneic lymphocytes enhances corneal graft survival. Invest Ophthalmol Vis Sci. 1990;31(10):1950-1956.
44. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270(5239):1189-1192.
45. Stuart PM, Griffith TS, Usui N, et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99(3):396-402.
46. Yamagami S, Kawashima H, Tsuru T, et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation. 1997;64(8):1107-1111.
47. Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;177(9):5928-5935.
48. Shen L, Jin Y, Freeman GJ, et al. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol. 2007;179(6):3672-3679.
49. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007;32(12):1005-1016.
50. Hegde S, Mellon JK, Hargrave SL, et al. Effect of alloantibodies on corneal allograft survival. Invest Ophthalmol Vis Sci. 2002;43(4):1012-1018.
51. Holan V, Vitova A, Krulova M, et al. Susceptibility of corneal allografts and xenografts to antibody-mediated rejection. Immunol Lett. 2005;100(2):211-213.
52. Bora NS, Gobleman CL, Atkinson JP, et al. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci. 1993;34(13):3579-3584.
53. Goslings WR, Prodeus AP, Streilein JW, et al. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest Ophthalmol Vis Sci. 1998;39(6):989-995.
54. Lass JH, Walter EI, Burris TE, et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci. 1990;31(6):1136-1148.
55. Hargrave SL, Mayhew E, Hegde S, et al. Are corneal cells susceptible to antibody-mediated killing in corneal allograft rejection? Transpl Immunol. 2003;11(1):79-89.
56. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-244.
57. Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci. 1997;38(6):1277-1282.
58. Apte RS, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol. 1996;156(8):2667-2673.
59. Apte RS, Sinha D, Mayhew E, et al. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160(12):5693-5966.
60. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol. 1986;136(10):3916-3920.
61. Chauhan SK, Saban DR, Lee HK, et al. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol. 2009;182(1):148-153.
62. Rayner SA, Larkin DFP, George AJT. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci. 2001;42:1568-1573.
63. Comer RM, King WJ, Theoharis S, Ardjomand N, George AJT, Larkin DFP. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci. 2002;43:1095-1103.
64. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation. 2001;71(9):1214-1220.
65. Klebe S, Coster DJ, Sykes PJ, et al. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol. 2005;175(4):2219-2226.
66. Ritter T, Yang J, Dannowski H, Vogt K, Volk HD, Pleyer U. Effects of interleukin-12p40 gene transfer on rat corneal allograft survival. Transpl Immunol. 2007;18(2):101-107. (Pubitemid 350086954)
67. Beutelspacher SC, Pillai RG, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol. 2006;36:690-700.
68. Gong N, Pleyer U, Vogt K, et al. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest Ophthalmol Vis Sci. 2007;48:1043-1052
69. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126(1):71-77.
70. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004;10(8):813-815.
71. Camelo S, Kezic J, McMenamin PG. Anterior chamberassociated immune deviation: a review of the anatomical evidence for the afferent arm of this unusual experimental model of ocular immune responses. Clin Exp Ophthalmol. 2005;33(4):426-432.
72. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42(6):1293-1298.
73. Plskova J, Holan V, Filipec M, Forrester JV. Lymph node removal enhances corneal graft survival in mice at high risk of rejection. BMC Ophthalmol. 2004;4(1):3.
74. Williams KA, Esterman AJ, Bartlett C, Holland H, Hornsby NB, Coster DJ. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation. 2006;81(6): 896-901.
75. Chatel M-A, Larkin DFP. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol. 2010 (in press).
76. Williams KA, White MA, Ash JK, Coster DJ. Leukocytes in the graft bed associated with corneal graft failure: analysis by immunohistology and actuarial graft survival. Ophthalmology. 1989;96:34-44.
77. Nguyen NX, Martus P, Seitz B, Cursiefen C. Atopic dermatitis as a risk factor for graft rejection following normal- risk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2009;247(4):573-574.
78. Niederkorn JY, Chen PW, Mellon J, Stevens C, Mayhew E. Allergic airway hyperreactivity increases the risk for corneal allograft rejection. Am J Transplant. 2009;9(5):1017-1026.
79. Beauregard C, Stevens C, Mayhew E, Niederkorn JY. Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J Immunol. 2005;174(11):6577-6581.
80. Flynn TH, Ohbayashi M, Ikeda Y, Ono SJ, Larkin DFP. The effect of allergic conjunctival inflammation on the allogeneic response to donor cornea. Invest Ophthalmol Vis Sci. 2007;48:4044-4049.